Skip to main content
PLUR
NASDAQ Life Sciences

Major Investor Alexandre Weinstein's Stake Confirmed at 35%; 625,000 Warrants Expire

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.09
Mkt Cap
$22.55M
52W Low
$1.99
52W High
$5.96
52W Position info
5.0% above low
Off High info
65% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

PLUR is trading near its 52-week low of $1.99 (5.0% above the low) on light trading volume (0.2× avg).

Summary

Major investor Alexandre Weinstein's beneficial ownership in Pluri Inc. is confirmed at 35% due to a beneficial ownership blocker, and 625,000 CHLP Common Warrants have expired, reducing potential dilution.


Key Events · Ownership and Investor Activity · PLUR

  • Major Investor Ownership Confirmed

    Alexandre Weinstein's aggregate beneficial ownership is confirmed at 35.00% of Pluri Inc.'s common stock, capped by a beneficial ownership limitation, despite a calculated 38.01%.

  • Warrant Expiration Reduces Potential Dilution

    625,000 CHLP Common Warrants, previously held by Chutzpah Holdings LP (beneficially owned by Mr. Weinstein), expired on June 30, 2026, reducing potential future share dilution.

  • Detailed Breakdown of Holdings

    The filing provides a comprehensive breakdown of Mr. Weinstein's complex holdings through Chutzpah Holdings Ltd (18.5%), Chutzpah Holdings LP (16.37%), and Plantae Bioscience Ltd (4.18%), along with directly held shares and RSUs.


Analysis · PLUR · Life Sciences

This Schedule 13D/A provides an important update on the beneficial ownership of Alexandre Weinstein, a key investor who has recently provided critical funding to the company amidst its liquidity challenges. The filing confirms his aggregate beneficial ownership at 35%, capped by a beneficial ownership blocker, despite a calculated higher percentage. Crucially, it also discloses the expiration of 625,000 CHLP Common Warrants, which reduces potential future dilution for existing shareholders. This detailed clarification of a major investor's stable, albeit capped, stake and the reduction in potential dilution are significant for a company facing financial distress.

At the time of this filing, PLUR was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.6M. The 52-week trading range was $1.99 to $5.96. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLUR - Latest Insights

PLUR
Jul 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.81 info
Change: +$0.070 (+4%) info
Market Cap: $19.637M info
PLUR
Jul 14, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.68
Real-time Price: $1.81 info
Change: +$0.130 (+8%) info
Market Cap: $19.637M info
PLUR
Jul 13, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.63
Real-time Price: $1.81 info
Change: +$0.180 (+11%) info
Market Cap: $19.637M info
PLUR
Jun 22, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.02
Real-time Price: $1.81 info
Change: -$0.210 (-10%) info
Market Cap: $19.637M info
PLUR
Jun 22, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.02
Real-time Price: $1.81 info
Change: -$0.210 (-10%) info
Market Cap: $19.637M info